The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.
Soria-Bretones I, Casás-Selves M, Samanta M, Groff D, Murray J, Fletcher JI, Farrel A, Pastor S, Patel K, Goodfellow E, Li L, Caron C, Shiwram A, Kim H, Henry D, Laterreur N, Bowlan J, Krytska K, Neuhauser SB, Stearns TM, Schubert JA, Wu J, Surrey LF, Martinez D, Mak C, Brand J, Wesley C, Somers K, Álvarez-Quilón A, Vallée F, Nejad P, Schonhoft JD, Li J, Veloso A, Young JTF, Hyer ML, Morris SJ, Mossé YP, Marshall CG, Haber M, Zimmermann M, Maris JM.
Soria-Bretones I, et al. Among authors: li j, li l.
Nat Commun. 2026 Jun 13. doi: 10.1038/s41467-026-74061-5. Online ahead of print.
Nat Commun. 2026.
PMID: 42288516
Free article.